Abstract:Lipoprotein-derived nanotherapeutics based on endogenous lipid supramolecules have been regarded as an exceptional and promising approach for anti-tumor drug delivery. However, certain challenges associated with the main component apolipoprotein, such as limited availability, high cost, and insufficient specificity of relevant receptor expression, pose significant barriers to its widespread development and application. The objective of this study is to fabricate lipoprotein-mimicking nanocomposites, denoted as CA-P-rHDL by substituting apolipoprotein with chenodeoxycholic acid (CA) modified bovine serum albumin (BSA), and subsequently assess their tumor-targeting capability and anti-tumor efficacy. CA modified BSA (CA-BSA) was successfully synthesized and characterized by quantifying the degree of protein substitution. Subsequently, a nanostructured lipid carrier (NLC) mimicking the hydrophobic core of natural lipoproteins was attached with CA-BSA to form a lipoprotein-mimic nanocomplex termed as CA-rHDL. CA-rHDL was endowed with lipoprotein-like structures, favorable particle size, zeta potential and excellent paclitaxel encapsulation (termed as CA-P-rHDL). The internalization of CA-rHDL by HepG2 cells exhibited significantly superior efficiency, with a notably higher in HepG2 cells compared to LO2 cells. Confocal laser scanning microscopy revealed that CA-rHDL evaded lysosomal degradation and was evenly distributed throughout the cells. CCK-8 studies demonstrated that CA-P-rHDL exhibited significantly superior inhibition of tumor cells growth compared to other paclitaxel formulations in vitro . Moreover, in vivo imaging observation in H22 tumor-bearing mouse models exhibited a rapid and consistent accumulation of CA-rHDL within tumors, while CA-P-rHDL demonstrated remarkable efficacy against cancer in these mice. These exceptional capabilities of CA-P-rHDL can be attributed to the synergistic targeting effect facilitated by the combination of CA and BSA, rendering it a promising and versatile drug delivery system for targeted anticancer therapy. Consequently, CA-P-rHDL established a highly potential platform for simulating the reconstitution of supramolecular nanovehicles.

Research progress of high-density lipoprotein as an antitumor drug carrier in cancer

Reconstituted high density lipoprotein (rHDL), a versatile drug delivery nanoplatform for tumor targeted therapy

Advances in liposome research in the field of antitumor

HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.

Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery

Liposomes for Tumor Targeted Therapy: A Review

The Targeted-liposome Delivery System of Antitumor Drugs

Application of liposomes as carriers of anti-tumor drugs

Strategies for Liposome Drug Delivery Systems to Improve Tumor Treatment Efficacy

Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery

Lipoprotein-mimicking nanotherapeutics reconstituted with chenodeoxycholic acid modified protein for efficient tumor?targeting

A potential carrier for anti-tumor targeted delivery-hyaluronic acid nanoparticles

Research progress in tumor therapy of carrier-free nanodrug

Hyaluronic Acid-Based Nanocarriers for Anticancer Drug Delivery

Research Progress in Exosome-Based Nanoscale Drug Carriers in Tumor Therapies

Advances in Targeting Drug Biological Carriers for Enhancing Tumor Therapy Efficacy

Tumor targeting using liposomal antineoplastic drugs

Natural discoidal lipoproteins with tiny modification for tumor extracellular dissociation in antitumor chemoimmunotherapy

Research Progress of Carrier-Free Antitumor Nanoparticles Based on Phytochemicals

Progress of Liposome as Drug Carriers

Effect of Size and Pegylation of Liposomes and Peptide-Based Synthetic Lipoproteins on Tumor Targeting.